Other Information
−Removed: Pharmaceuticals MAY-66 License Termination
−Removed: May 10, 2021, Mayfield terminated the License Agreement (the “TGV License”) with TGV-Health, LLC and affiliated entities
−Removed: (collectively, “TGV”), pursuant to which it acquired intellectual property rights for use in the women’s health field,
−Removed: related to Mayfield’s proprietary drug candidate MAY-66.
−Removed: Concurrent with the termination, TGV returned to Mayfield 300,000 shares
−Removed: of Mayfield’s common stock, constituting all of the equity held by TGV.
−Removed: Mayfield has no outstanding or remaining obligations under
−Removed: the TGV License.
−Removed: Pharmaceuticals MAY-44 APA Termination
−Removed: May 10, 2021, Mayfield and Harrow terminated their asset purchase agreement dated January 2020 for intellectual property rights
−Removed: associated with Mayfield’s drug candidate MAY-44 with Elle Pharmaceutical LLC (the “MAY-44 APA”).
−Removed: the termination, Mayfield re-acquired 350,000 shares of its common stock from Elle for $350.
−Removed: Mayfield has no outstanding
−Removed: or remaining obligations related to the MAY-44 APA.
−Removed: License Termination
−Removed: May 10, 2021, Stowe terminated the License Agreement (the “Stowe License”) with TGV, pursuant to which it acquired intellectual
−Removed: property rights for use in the ophthalmic field, related to Stowe’s proprietary drug candidate STE-006.
−Removed: Concurrent with the termination,
−Removed: TGV returned to Stowe 1,750,000 shares of Stowe’s common stock, constituting all of the equity held by TGV.
−Removed: Stowe has no outstanding
−Removed: or remaining obligations under the Stowe License.
Certificate of Designation designating the Series B Cumulative Preferred Stock of the Company (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K of the Company filed with the SEC on May 5, 2021).
7 unchanged sentences
(incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K of the Company filed with the SEC on May 5, 2021).
+Added: License and Supply Agreement, dated as of July 25, 2021, by and between the Company and Sintetica, S.A.
+Added: First Amendment to the Harrow Health, Inc.
+Added: 2017 Incentive Stock and Awards Plan (incorporated herein by reference to Appendix A to the Company’s Definitive Proxy Statement filed with the SEC on April 23, 2021).
Certification of Mark L.
13 unchanged sentences
XBRL Taxonomy Extension Presentation Linkbase Document
−Removed: cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, has been formatted in Inline
+Added: cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, has been formatted in Inline
+Added: of this exhibit have been omitted in compliance with Item 601 of Regulation S-K.
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
+Added: Harrow Health, Inc.
+Added: August 10, 2021
Executive Officer and Director
Executive Officer)
−Removed: Financial Officer (Principal Financial and Accounting Officer)
+Added: Financial Officer
+Added: Financial and Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.